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Abstract
Background: The innate immune responses to virus infection are initiated by either Toll-like receptors (TLR3/7/8/9) or
cytoplasmic double-stranded RNA (dsRNA)-recognizing RNA helicases RIG-I and MDA5. To avoid causing injury to the host,
these signaling pathways must be switched off in time by negative regulators.
Methodology/Principal Findings: Through yeast-two hybrid screening, we found that an ubiquitin-like protein named
protein linking integrin-associated protein to cytoskeleton 1(PLIC-1 or Ubiquilin 1) interacted with the Toll/interleukin-1
receptor (TIR) domain of TLR4. Interestingly, PLIC-1 had modest effect on TLR4-mediated signaling, but strongly suppressed
the transcriptional activation of IFN-b promoter through the TLR3-Trif-dependent pathway. Concomitantly, reduction of
endogenous PLIC-1 by short-hairpin interfering RNA (shRNA) enhanced TLR3 activation both in luciferase reporter assays as
well as in new castle disease virus (NDV) infected cells. An interaction between PLIC-1 and Trif was confirmed in co-
immunoprecipitation (Co-IP) and GST-pull-down assays. Subsequent confocal microscopic analysis revealed that PLIC-1 and
Trif colocalized with the autophagosome marker LC3 in punctate subcellular structures. Finally, overexpression of PLIC-1
decreased Trif protein abundance in a Nocodazole-sensitive manner.
Conclusions: Our results suggest that PLIC-1 is a novel inhibitor of the TLR3-Trif antiviral pathway by reducing the
abundance of Trif.
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Introduction
Extensive studies in the past decade have now revealed a
number of innate immune sensors including the Toll-like
receptors, RIG-1, MDA-5, DAI, which recognize molecular
patterns present on pathogens and rapidly alert the host to the
presence of potentially dangers [1,2,3]. Specific to virus detection,
cell surface or endosome-associated TLRs recognize viral DNA or
RNA and initiate MyD88 or Trif-dependent signaling cascades
that activate transcription factors NF-kappaB (NF-kB) and
interferon regulatory factors (IRFs) and, ultimately, turn on the
transcription of hundreds of cellular genes, of which type I
interferons (IFNs) are best known for their antiviral effects. In
addition, RNA helicase RIG-I or MDA5 can detect intracellular
viral double-stranded RNA and activate NF-kB and IRFs via the
adaptor protein MAVS/IPS-1/VISA/Cardif, a CARD domain
containing protein that is anchored to the mitochondrial
membrane [4,5,6,7]. Interestingly, viruses such as hepatitis C
virus (HCV) have evolved mechanism to interfere with the critical
innate signaling pathways, allowing escape from the host immune
surveillance [5,8,9,10].
Ubiquitin is a 76-amino-acid globular protein that is nearly
identical throughout eukaryotes [11]. Ubiquitylation, the process
of conjugating ubiquitins to other proteins, plays a pivotal role in
the physiological turnover or the degradation of proteins in
response to environmental stimuli. Historically, ubiquitylation of a
protein is known to target it to 26S proteasome for degradation. It
is increasingly realized that ubiquitylation also plays a unique role
in regulating multiple cell signaling pathways [12]. For example,
the transcription factor NF-kB is normally held in cytoplasm in
association with its inhibitor called I-kB. Upon cell stimulation
with interleukin -1 (IL-1) or TLR ligands, I-kB is phosphorylated
by an I-kB kinase (IKK) complex [12]. The phosphorylation of I-
kB triggers its K48-linked polyubiquitylation and its subsequent
degradation by the 26S proteasome, which then releases NF-kB
for activation [12].
Although multiple studies revealed the involvement of
ubiquitylation and de-ubiquitylation in regulating IL-1R/
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described that the ubiquitin-mediated receptor degradation
negatively regulated TLR signaling [13]. In that study, a novel
TLR interacting protein termed Triad 3A was demonstrated to
be an E3 ligase which interacts with several TLRs. Triad3A
induces ubiquitylation of TLR9 and TLR4 but not TLR2,
which then targets them for proteasomal degradation. As a
result of this, the TLR-mediated activation of NF-kBw a s
suppressed. Most recently, it is shown that Triad3A promoted
down-regulation of two TIR domain-containing adapter
proteins, TIRAP and Trif, RIP1 which is the essential
downstream protein of TNF-a signaling [14], as well as TRAF3
which mediates the RIG-I/MAVS signaling pathway [15].
Thus, ubiquitylation and degradation of innate signaling
molecules by Triad3A represents a novel pathway by which
the host limits the intensity and duration of innate signaling
pathways.
In a yeast two-hybrid screening study, we identified an
ubiquitin-like protein PLIC-1 as a potential interacting partner
of the TIR domain-containing proteins. Using luciferase
reporter assays, we found that PLIC-1potently suppressed the
TLR3-Trif-dependent IFN-b promoter activity while exerted
minimal effect on TLR4-mediated NF-kB activation or TLR7-
or MAVS-dependent IFN-b promoter activity. When endoge-
nous PLIC-1 was reduced by short-hairpin based interfering
RNA (shRNA), new castle diseases virus (NDV) became
hypersensitive to poly I:C treatment, reinforcing the idea that
PLIC-1 negatively regulates TLR3-pathway. Coimmunopreci-
pitation (Co-IP) studies revealed that PLIC-1 coprecipitated
with Trif, but not TLR3. A GST-pull down further showed that
the ubiquitin associated (Uba) domain of PLIC-1 directly pulled
down Trif. Subsequent confocal microscopy revealed that
PLIC-1 co-localized both with Trif and LC3, an autophago-
some marker, in punctate structures within the cytoplasm.
Furthermore, overexpression of PLIC-1 decreased the cellular
abundance of Trif via a pathway that can be blocked by
Nocodazole, but not MG132. Altogether, these data suggest that
PLIC-1 is a novel inhibitor of TLR3-Trif signaling pathway by
decreasing the abundance of the innate signaling adaptor
molecule Trif via the autophagic pathway.
Results
Identification of PLIC-1 as a TIR-interacting protein
To screen for novel regulators of TLR-pathway, we conducted a
yeast-two hybrid assay using the Clontech Matchmaker III system
(Palo Alto, CA) according to the manufacturer’s instruction. The
intracellular domain (TIR domain) of TLR4 was chosen as the
bait. 36 million clones from a human leukocyte cDNA library
HL4021B were screened and 6 clones showed strong interaction
with bait. After sequencing, all six clones were found to contain
partial fragments matching a gene named PLIC-1 in the NCBI
database.
PLIC-1 contains an amino terminal ubiquitin-like domain (Ubl)
and carboxyl terminal ubiquitin associated domain (Uba) as well as
two internal repeats of ,85 amino acids that contain Sti I motifs.
PLIC-1 is known to bind to membrane proteins including
presenilins and GABA receptors [16,17]. PLIC-1 was reported
to bind ubiquitylated proteins and ubiquitin ligases such as E6AP
and bTRCP, and proteasome subunits [18]. These interactions
are thought to interfere with normal targeting of proteins for
proteasome-dependent-degradation, resulting in enhanced stabil-
ity potential affecting the signaling pathways in which these
proteins are involved.
PLIC-1 exerted a strong inhibitory effect on
Trif-dependent signaling in reporter assays
We first investigated the role of PLIC-1 in regulating TLR4
signaling using luciferase reporter assays. To our surprise,
overexpression of PLIC-1 had no effect on TLR4-dependent
NF-kB activation (Fig. 1A), while modestly suppressed the
activation of an ISG promoter driven luciferase reporter by a
constitutive TLR4 activator, CD4-TLR4 [19] (Fig. 1B). We then
sought to explore its effect on other TLR signalings. To this end,
we performed a series of reporter assays and found that PLIC-1 is
a potent inhibitor of TLR3-Trif-pathway. First, overexpression of
PLIC-1 inhibited the Trif-dependent activation of NF-kB-
dependent reporter (Fig. 1C) as well as p125-Luc whose
transcription is under the control of IFN-b promoter [20]
(Fig. 1D), but had negligible effect on the basal transcription of
the reporter gene (data not shown). To rule out the possibility that
this inhibition was associated with a specific tagged PLIC-1, YFP-
or flag-tagged PLIC-1 constructs were included in the transfection
and similar dose-dependent inhibition was observed (Fig. 1E and
data not shown). Of note, expression of PLIC-1 in 293T cells did
not inhibit the activation of p125-Luc by overexpressing IRF-3,
suggesting that PLIC-1 exerts its inhibitory effect at a step that is
upstream of IRF-3 (Fig. 1F). To investigate whether PLIC-1 exerts
effects on other innate immune signaling, similar studies were
repeated on HEK-TLR7 stable cell line and cells transfected with
MAVS. It was observed that PLIC-1 failed to have any effect in
either case (Fig. 1G&H). Thus, the inhibitory effect of PLIC-1
appeared to be limited to Trif signaling. Because Trif is absolutely
required in TLR3 pathway whose activation increases transcrip-
tion of IFN-b gene [21], we assessed the effect of PLIC-1 on TLR3
activation. In mouse macrophage cells J774A.1 that were
stimulated with poly I:C (TLR3 ligand), the activation of IFN-b-
driven luciferase decreased as the amount of PLIC-1 increased
(Fig. 1I). Together, these data suggest that PLIC-1 negatively
modulates the TLR3-Trif pathway.
Reduction of endogenous PLIC-1 enhanced TLR3-Trif
signaling
Subsequently, we designed short hairpin interfering RNA
(shRNA) knocking down the expression of PLIC-1. The shRNA
is expressed from a retroviral vector under the control of human
H1 promoter [22]. Two sequences were selected to target three
different regions of hPLIC-1. The shRNA harboring a scrambled
sequence and the one targeting mouse PLIC-1(LMP) were
included as controls for specificity. To monitor the knockdown
effect, shRNA vectors were first transfected along with HA-
hPLIC-1 construct in 293T cells. Two shRNA constructs targeting
to human PLIC-1 specifically suppressed the expression of HA-
hPLIC-1 expression in a dose-dependent manner (Fig. 2A). The
shRNA construct (#1602) was subsequently employed to reduce
the endogenous PLIC-1 (Fig. 2B) and this led to enhanced
activation of Trif-dependent IFN-b promoter activity (Fig. 2C).
Moreover, transfection with this construct enhanced the activation
of the IFN-b-promoter activity (p125-Luc) upon poly I:C
stimulation (Fig. 2D). Taken together, these results reinforced
the finding that PLIC-1 inhibits the TLR3/Trif-mediated innate
immune signaling activation.
Reduction of endogenous PLIC-1 rendered NDV
hypersensitive to Poly I:C treatment
The above experiments were carried out using luciferase
reporter assays. In order to validate the observations in an
infection system, we generated PLIC-1 stable knockdown cells in
PLIC-1 Inhibits TLR3 Activation
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NDV virus carrying the green fluorescent protein (GFP) in its
genome. Because NDV is highly sensitive to type I interferon
treatment, such a system allows rapid and sensitive monitoring of
bioactivity of type I interferon. Shown in Fig. 3, polyI:C
stimulation of A549 cells modestly reduced the NDV-GFP
infection, while the inhibition was significantly enhanced in
PLIC-1 knockdown cells. When the bioactivity of type I interferon
Figure 1. Overexpression of PLIC-1 inhibited TLR3 signaling. A. TLR4/MD2 stable HEK cells were transfected with a NF-kB driven luciferase
reporter plasmid and increased amount of HA-PLIC-1. 24 hours post-transfection, cells were stimulated with LPS (100 ng/ml) and incubated for
additional 24 hours prior to luciferase reporter assay. B. 293T cells were transfected with pISRE-Luc (100 ng), CD4-TLR4 (50 ng), and increased
amount of HA-PLIC-1 for luciferase reporter assay. C. 293T cells were transfected with Trif, kB-Luc, and increased amount of HA-PLIC-1 plasmids. A
total of 2 mg DNA was transfected in each well in a 12-well plate. 48 hours following transfection, luciferase activity was determined. Data was
normalized against renilla luciferase which was transfected as an internal control. Experiments in D were carried out similarly as in C except that
p125-Luc, plasmid was used. E. p125-Luc reporter was transfected along with Trif and YFP-PLIC-1 plasmids. F. Experiments were carried out similarly
as in D except that 0.3 mg IRF3 expression plasmid was added to stimulate p125-luc reporter. G. HEK cells stably expressing TLR7 were transfected
with indicated constructs and stimulated with TLR7 agonist, imiquimod (10 mg/mL) for 24 hours followed by luciferase reporter assay. H. 293T cells
were transfected with MAVS and increasing amount of PLIC-1 for reporter assays. I. 2.5610
5 J774A.1 cells were transfected with indicated plasmids.
Poly I:C(40 mg/ml) was added to cells for additional period of 24 hours prior to measuring luciferase activity. Data were normalized by using renilla
luciferase as an internal control. The error bars in above experiments represent the standard deviation accumulated from at least three experiments.
doi:10.1371/journal.pone.0021153.g001
PLIC-1 Inhibits TLR3 Activation
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21153was compared by calculating the percentage of NDV infected
cells, PLIC-1 knockdown A549 cells showed higher level of type I
interferon activity. Altogether, these results reinforced that notion
that PLIC-1 is an inhibitor of the TLR3 pathway.
PLIC-1 interacts with Trif
To explore the interaction between PLIC-1 and Trif, we first
conducted Co-IP experiment. Fig. 4A showed that transiently
expressed PLIC-1 was able to precipitate co-expressed Trif, but
not the negative control protein. Moreover, in a separate
experiment, we failed to pull down TLR3 and PLIC-1 together
(data not shown). In order to determine which domain of PLIC-1
interacts with Trif, we produced GST fusion proteins containing
PLIC-1 Uba domain alone, or PLIC-1 devoid of Uba or both Uba
and Ubl domain and conducted a pull-down assay with Flag-Trif.
It was found that the Uba domain of PLIC-1 alone is necessary
and sufficient to bind Trif (Fig. 4B).
Co-localization of PLIC-1, LC3, and Trif
Endogenous PLIC-1 was previously documented to concentrate
at perinuclear aggresomes [23]. A recent study, however, indicated
both PLIC-1 and 2 associate with autophagosomes and depletion
of PLICs inhibited autophagosome degradation during nutrient
starvation [24]. Trif was found in some speckle-like structures in
the cytosol and did not co-localize with TLR3, but transiently
associated with TLR3 upon polyI:C stimulation in the same
speckle-like structures [25]. Overexpressed Trif reportedly multi-
merizes and localizes to punctate cytoplasmic structures referred to
as the Trif ‘‘signalosome’’ [23,24]. To investigate the subcellular
distribution pattern of PLIC-1 and Trif, YFP-PLIC-1 and Flag-
Trif were transfected into human hepatoma cell line Huh7.5.1
cells and analyzed by confocal microscopy. Huh7.5.1 cells were
chosen for this part of the study because they produce very little
TLR3 and Trif at endogenous level and have a relatively large
volume of cytoplasm [26], which makes them ideal for imaging
cytoplasmic proteins. To avoid potential artifact due to overex-
pression, we intentionally kept the amount of DNA plasmid very
low in this study. It was found that YFP-PLIC-1 was concentrated
into punctate ring-like structures (Fig. 5A), similar to what has
been reported [24,27]. Immunostaining revealed a rather punctate
subcellular distribution pattern for Flag-Trif alone, which is also
consistent with previous reports [25,28]. Of note, we observed a
pronounced co-localization of YFP-PLIC-1 and Flag-Trif in
punctate cellular structures (Fig. 5B). Of note, GFP itself did not
co-localize with Flag-Trif (Fig. 5C). By contrast, there was no co-
localization of PLIC-1 and MAVS at all (Fig. 5D). Attempts to
image ectopically expressed TLR3 in Huh7.5.1 cells were not
successful due to the extremely low level of expression.
To further explore the nature of the observed vesicular
structures, we transfected cells with a RFP tagged LC3 to indicate
the formation of autophagosomes. Remarkably, PLIC-1 largely
co-localized with LC3 (Fig. 6A). Moreover, when similar
Figure 2. Reduction of PLIC-1 level enhanced TLR3-Trif-mediated signaling. A. Knocking down PLIC-1 by shRNA. 0.1 mg of HA-PLIC-1 was
transfected with 0.1,1,2,4 mg of indicated shRNA constructs in 293T cells. Western blot was performed to detect HA-PLIC-1. B. shRNA 1602, 733, the
scramble construct, and LMP (targeting mouse PLIC-1) were expressed in 293T cells. Knockdown of endogenous PLIC-1 was verified by western
blotting using an anti-PLIC-1 antibody. C. Indicated combinations of constructs were transfected into 293T cells. 48 hours following transfection,
luciferase activity was determined and normalized against renilla luciferase. D. Reduction of PLIC-1 by shRNA 1602 enhanced the activation of IFN-b
promoter activity by poly I:C stimulation. 293T cells were transfected with indicated plasmids and further stimulated with poly I:C (40 mg/ml) for
24 hours prior to lysis. Notice that transfection with shRNA construct itself did not activate the IFN-b promoter.
doi:10.1371/journal.pone.0021153.g002
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least a portion of Trif co-localized with LC3 (Fig. 6B&C). These
results pointed out that autophagosomes may be where the PLIC-
1 and Trif complex locates.
Downregulation of Trif by PLIC-1
In order to gain mechanistic insight into the action of PLIC-1-
dependent inhibition, we transfected 293T cells with a plasmid
encoding Trif along with specified amounts of PLIC-1 plasmid. After
18 hours, cell lysates were prepared and analyzed by immunoblot of
Trif expression. PLIC-1 decreased the abundance of Trif but not an
irrelevant protein named Flap (a negative control) in a dose-
dependent manner (Fig. 7A). Notably, Flag-Flap was transcribed by a
heterologous promoter (CMV promoter) from the same vector in
which Trif was cloned. Therefore, PLIC-1 appears to decrease Trif
abundance at protein level, presumably via protein degradation.
There are two known pathways for protein degradation:
ubiquitin-proteasomal pathway as well as the autophagy-depen-
dent pathways. Since PLIC-1 has been implicated in both
pathways, we added the proteasome inhibitor MG132 and the
microtubule inhibitor Nocodazle, which is known to block the
autophagy-lysosome pathway [29], to the cell cultures. Shown in
Figure 7B&C, addition of Nocodazole significantly reversed the
PLIC-1-dependent Trif degradation, whereas the effect of MG132
on this process was nearly negligible.
Discussion
Innate immune signalings mediated by TLRs, RIG-1, and
MDA5 are critical in recognizing microbial pathogens and
triggering the first line of host defense. Unchecked signaling
activation, however, can lead to excessive production of
inflammatory mediators that cause tissue damages. Studies in
recent years have now revealed a number of negative regulators of
innate immune signaling pathways, such as IL-1R-associated
kinase M (IRAK-M) [30], CYLD [31], SIGIRR [32], suppression
of cytokine signaling 1 (SOCS1) [33], etc. Most recently, Triad3A
was demonstrated to act as an E3 ubiquitin-protein ligase and
enhance ubiquitylation and proteolytic degradation of several
TLRs and RIP1, resulting in the attenuation of TLR signalings
[13,14]. The identification of PLIC-1 now adds a new member to
this long list of negative regulators.
PLIC-1 is a type 2 ubiquitin-like (ubl) proteins. In contract to the
small-sized type 1 ubl proteins that are covalently linked to target
proteins in a fashion similar to ubiquitin, type 2 ubl proteins are not
ligated to other proteins and their functions are poorly defined.
There are four members of PLIC in mouse and human [18]. Data
from functional analyses suggest a role for PLICs in the in vivo
degradation of several proteins known to be ubiquitylation-
dependent substrates of the proteasome [18,34,35]. Interestingly,
in transfection studies, PLICs either inhibit or promote ubiquitin-
dependent proteasome degradation [16,18,36]. Moreover, inhibi-
tion of G protein signaling by PLIC-1 is independent of proteasome
activity [37].Likeubiquitin, theexpression ofPLICs is ubiquitous in
almost all cell types [17,31]. Particularly interesting, it is recently
shown that PLIC-1 and 2 locate to autophagosomes [23].
Despite that our study initially identified PLIC-1 as a TLR4
interacting partner, we failed to observe any noticeable effect of
PLIC-1 on TLR4-dependent NF-kB activation in reporter assays. It
must be pointed out, however, that TLR4 signals through MyD88
and Trif sequentially [38] to activate a second-phase signaling. LPS
stimulation first triggers TLR4-MyD88-depdent signaling from
plasma membrane and activates NF-kB; endocytosis of TLR4 then
quenches MyD88-dependent signaling and starts a second phase of
Figure 3. PLIC-1 blocked TLR3-induced production of IFN-a during NDV infection. The parental human lung cancer cell line A549 or the
A549 stably expressing shRNA #1602 and 733 (specifically target hPLIC-1) or the negative control shRNA (LMP) were stimulated with poly I:C (100 mg/
ml) for 24 hours and then infected by NDV-GFP (MOI 1). 12 hours post-infection, images were taken to visualize cells that had been productively
infected by the green virus. Recombinant IFN-a was added as a positive control to suppress NDV infection. Percentages of positive infection were
calculated by averaging the number of green cells over that of blue cells (DAPI staining of nuclei) in 4 fields. The numbers were indicated in the upper
right corner of each merged image.
doi:10.1371/journal.pone.0021153.g003
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event was more obvious in dendritic cells (DCs) and bone marrow
derived macrophages, which were not employed in this study, the
observed modest inhibition of PLIC-1 on TLR4-dependent ISG
promoter activity could be more pronounced should DCs be
examined. Nonetheless, we found that PLIC-1 inhibited the TLR3-
Trif-dependent signaling both in reporter assays as well as during
NDV infection. TLR3 detects double-stranded RNA (dsRNA),
which is a common intermediate during virus replication, and
signals exclusively via the adaptor protein Trif. The cell biology of
TLR3 and Trif has been very interesting because TLR3 reportedly
localizes to endosomes or phagolysosomes [39,40,41,42]. Trif,
however, does not co-localize with TLR3 at resting state, but
transiently associates with TLR3 upon ligand engagement and
initiates the signaling [24]. The exact location of intracellular Trif
remains mysterious as immunostaining of Trif did not co-localize
with any known early or late endosomal marker [25,27]. Our
finding that Trif co-localized with PLIC-1 and LC3 raises an
interesting possibility that Trif may localize to autophagosome.
Interestingly, results from the GST pull-down assay demonstrated
that the Uba domain of PLIC-1 interacts with Trif, and this is also
the domain that is reportedly required for PLIC-1 to target to
autophagosomes [24]. Remarkably, ample evidence now highlights
a connection between TLR-mediated innate immunity and
autophagy. For instance, LPS increased autophagosomes and
autophagy-mediated cell death of infected macrophages [43]. In
addition, autophagy was shown to be essential for TLR7-mediated
recognition of RNA viruses [43]. In future, it will be interesting to
determine whether co-localization of Trif and PLIC-1 occurs
constitutivelyoruponTLR3 activation.Thislikely requiresimaging
both proteins at endogenous level in cells or near endogenous level
in a stable cell line that expresses tagged proteins.
In our study, expression of PLIC-1 diminished the level of Trif
when expressed from a transfected plasmid, suggesting PLIC-1
may accelerate the degradation of Trif. Cellular proteins can be
degraded via two pathways: the ubiquitin-proteasomal pathway
and the autophagic-lysosomal pathway. The ubiquitin-proteasome
pathway is fundamental to protein degradation [44]. In brief,
ubiquitin is initially activated by the ubiquitin-activating enzyme
known as enzyme-1 (E1), and then transferred to the ubiquitin-
conjugating enzyme (E2). Together with the ubiquitin-protein
ligase (E3), E2 covalently attaches ubiquitins to the target protein
at the e-amino group of a lysine residue. The polyubiquitin chain
finally signals 26S proteasome to degrade the ubiquitylated
proteins. The ubiquitin-like PLIC-1, however, has no enzymatic
activity and is not known to be covalently linked to any protein.
The autophagic pathway, on the other hand, offers an alternative
mechanism to proteasomes for the degradation of cytoplasmic
Figure 4. Interaction of PLIC-1 and Trif. A.2mg YFP-PLIC1or GFP and 2 mg Flag-Trif were cotransfected into 293T cells at 70% confluence in a 60-
mm plate. 48 hours post-transfection, cell lysates were prepared and subjected to M2 anti-Flag affinity resin. After extensive wash with PBS, proteins
were eluted by boiling the beads in 26sample buffer and separated on a SDS-PAGE. Western blotting was performed using indicated antibodies.
B. GST fusion proteins (around 2 mg) were mixed with cell lysates containing Flag-Trif for 2 hours and bound proteins were eluted from the GST
column and analyzed for the presence of Flag-Trif. One tenth of the input protein was loaded. A Coomassie stained gel image was included showing
the expression of each GST fusion protein.
doi:10.1371/journal.pone.0021153.g004
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organelles are first taken into phagosomes that fuse with lysosomes
into phagolysosomes in which proteins will be finally degraded by
lysosomal enzymes [47]. Since both PLIC-1 and Trif can localize
to autophagosomes and the PLIC-1-dependent effect on Trif is
sensitive to Nocodazole treatment, it is tempting to envision that
cells may utilize the authophagic pathway that typically degrades
cellular components during starvation to degrade Trif signalosome
and hence terminate the Trif-dependent innate signaling. Future
work is warranted to explore this novel mechanism in detail.
Materials and Methods
Cell Lines and reagents
293T (ATCC CRL-11268) cell line and the human hepatoma
cell line Huh7.5.1 (gift from Dr. F. Chisari) were cultured in
DMEM (Invitrogen Life Technologies) supplemented with 10%
FBS (HyClone), 1% penicillin, and 10 mg/ml streptomycin. The
mouse macrophage cell line J774 was a generous gift from Dr.
David Hackam (University of Pittsburgh School of medicine, PA).
J774 cell line was maintained in DMEM supplemented with 5%
penicillin and streptomycin, 1% NEAA, and 10% fetal bovine
serum (Hyclone). The human lung cancer cell line A549 (ATCC
CCL-185) was maintained in F12K media (ATCC 30-2004)
supplemented with 10% fetal bovine serum and 5% penicillin and
streptomycin. TLR4/MD2 stable cell line was obtained from Dr.
D. Golenbock (University of Massachusetts, Worcester). HEK/
TLR7 cell line was a generous gift of Dr. S. Saumendra
(University of Pittsburgh). Anti-HA, anti-Flag M2, and anti-
PLIC-1 (U7383) antibodies were purchased from Sigma.
DNA constructs
PLIC-1 N terminal and PLIC-2 full length plasmids were
obtained from the Howley lab (Boston). The NF-kB-Luc plasmid
Figure 6. PLIC-1 and Trif co-localized with LC3. The human hepatoma cell line Huh7.5.1 cells were seeded on glass cover slip and then transfected
with0.1 mg of YFP-PLIC-1 and RFP-LC3 (A), or 0.1 mg YFP-Trif andRFP-LC3 in HEK (B)o rH u h 7 . 5 . 1( C) cells in a 24-well plateformat. 24 hours post-infection,
cells were fixed and imaged using a Zeiss Meta LSM510 microscope. In all figures, co-localization was indicated as yellow dots in the merged images.
doi:10.1371/journal.pone.0021153.g006
Figure 5. PLIC-1 co-localized with Trif. The human hepatoma cells Huh7.5.1, were seeded on glass cover slip and then transfected with 0.1 mgo f
YFP-PLIC-1 alone (A) or with 0.1 mg Flag-Trif (B) in a 24-well plate format. 24 hours post-infection, cells were fixed, permeabilized and stained with
anti-Flag M2 antibody. Confocal and differential interference contrast (DIC) images were taken with a Zeiss Meta LSM510 microscope. C. 0.1 mgo f
GFP expression plasmid was transfected with 0.1 mg Flag-Trif for confocal imaging. D. 0.1 mg of YFP-PLIC-1 expression plasmid was transfected with
0.1 mg Flag-MAVS into Huh7.5.1 cells for confocal imaging.
doi:10.1371/journal.pone.0021153.g005
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Pasadena, CA). The p125-luc reporter was provided by Dr. T.
Taniguchi (Graduate School of Medicine and Faculty of Medicine,
University of Tokyo) and contains the human IFN-b promoter
region (2125 to +19) inserted into the luciferase reporter plasmid.
The ISRE-Luc plasmid containing 5 copies interferon stimulation
response element (ISRE) from ISG54 promoter upstream of the
firefly luciferase was a gift of Dr. Kui Li (University of Tennessee
Health Science Center). YFP-TLR4, Flag-TLR4, HA-PLIC-1,
YFP-PLIC-1, Flag-PLIC-1, Fc-TLR4 and pMIR-DFT-empty
plasmid, YFP-Trif, Flag-Trif plasmids were constructed in the
lab. RFP-LC3 was a gift of Dr. C. Coyne (University of
Pittsburgh). GST fusion constructs were obtained from Dr. E.
Brown (University of California, San Francisco). pCL-10A1 which
is a retrovirus packaging vector was purchased from IMGENEX.
shRNA constructs targeting human PLIC-1 (1602, 733) or mouse
PLIC-1 (mLMP), as well as the one with the scrambled sequence,
were constructed in the lab (detailed information is available upon
request). pFlag-MAVS was kindly provided by Dr. J. Chen (UT
Southwestern Medical Center, Dallas, TX).
Transfection
Transfections of 293T and J774 cells were done using
lipofectamine 2000 (Invitrogen) reagent following the manufac-
turer’s instruction. Briefly, plasmids and media (amount depending
on the size of the well) were mixed together, and lipofectamine
2000 (26 of the amount of plasmid) was mixed with media in a
separate tube. Then media containing plasmids and media
containing lipofectamine were then mixed together, allowed to
sit for 15–20 minutes at room temperature, and added slowly to
the well. After 4 hours the media was replaced with fresh media
containing 5% penicillin and streptomycin, 1% NEAA, and 10%
fetal bovine serum. For transfection in J774 macrophage cell line,
macrophages were transfected according to AFCS (Alliance for
Cellular Signaling gateway) protocol of Transfection of Raw Cells.
16105 cells were plated in each well the day before transfection in
24-well plates. For each transfection, 1 ml Lipofectamine 2000 was
added to 25 ml Opti-MEM in a 1.5-ml Eppendorf tube. In another
tube the required amount of plasmid was added, mixed, and
allowed to sit for 5 min at room temperature. Then, 25 ml DNA
mixtures was added to the 25 ml Lipofectamine 2000 mixture and
mixed by pipetting. This mixture was incubated for 20 min at
room temperature. 200 ml RAWGMI was added to each well and
the plasmid/lipofectamine media was then added. After 3 hours
the media was removed and replaced with fresh RAWGM1. The
composition of RAWGMI media is (for 500 ml) DMEM 435 ml
(Final concentration 0.876), FBS 50 ml (Final concentration
10%), HEPES 10 ml (Final concentration 20 mM), L-Glutamine
5 ml (Final concentration 2 mM).
Western Blot and Immunoprecipitation
For cell lysate preparation, monolayer cells were lysed with a
lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5%
Nonidet P40, 50 mM NaF, 1 mM Na3VO4, 5 mM b-glycero-
phosphate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride) supplemented with a protease inhibitor mixture (Sigma)
on ice. Lysates were cleared by centrifuging at 14,0006 g for
20 min. Boiled samples in 26 SDS loading buffer were resolved
on a 10–12% SDS-polyacrylamide gel (SDS-PAGE). After
electrophoresis, the separated proteins were transferred onto a
nitro-cellulose membrane (Bio-Rad). The resulting blots were
blocked in 10% milk for 1 h, and then incubated with primary
antibody overnight at 4uC. The secondary antibody used in the
immunoblot was a 1:2000 dilution of HRP-linked anti-IgG,
followed by detection using the ECL reagents (Amersham). For
immunoprecipitation-coupled western blotting, a quantity of 50–
100 mg of total soluble extract was incubated with an appropriate
amount of beads conjugated with the specified Ab for 2 h at 4uC.
Alternatively, the antibody used for IP was added and kept in a
rotating condition for 3–4 hrs and then Protein A beads were
Figure 7. Overexpression of PLIC-1 decreased Trif abundance
in a Nocodazole-sensitive manner. A. 293T cells were transfected
with indicated plasmids. 48 hours post-transfection, lysates were
prepared and subjected to western blot analysis. HCV NS3/4A was
known to cleave Trif and was included as a positive control [8].
However, it only marginally reduced the level of Trif. PLIC-1 has no
effect on the expression of a protein named Flap, which was included as
a negative control here. B. 293T cells were transfected with 0.2 mg Flag-
Trif and indicated amount of HA-PLIC-1 plasmid for 24 hours. Cells were
then treated with 30 mM Nocodazole or MG132 (50 mM) for 6 hours
prior to cell lysis. Western blotting was performed to quantitate the
level of Flag-Trif, HA-PLIC-1. A non-specific band was indicated as the
loading control.
doi:10.1371/journal.pone.0021153.g007
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bound proteins were eluted and then separated on a SDS-PAGE
followed by western blotting.
Reporter assay
For the luciferase reporter assay, 0.25 million 293T cells/well
were seeded in 24-well plates. The next day, cells were transfected
with lipofectamine 2000 (Invitrogen Life Technologies). A
specified amount of DNA was added into each transfection and
an empty pcDNA3.1 plasmid was included when necessary (filler
DNA) to keep the total amount of DNA same in each transfection.
When indicated, cells were treated with various stimuli for
specified time periods. Cells were harvested between 24 and
48 h after transfection and luciferase activity was measured using
the luciferase assay system (Promega). To control for transfection
variations, 0.05 mg Renilla luciferase plasmid whose transcription
is under the control of the neutral constitutive HSV-thymidine
kinase promoter (pRL-TK) was included in each transfection
(internal control). For all experiments, the data presented are the
mean 6 the standard deviation (SD) of duplicate or triplicate
samples and were repeated at least twice.
NDV-GFP virus production
NDV-GFP virus was a generous gift from Dr. Chris Basler
(Mount Sinai School of Medicine, NYC) and was produced in 10-
days old embryonated eggs (Charles River Laboratories Interna-
tional, Inc. Wilmington, MA). The inoculated eggs were incubated
for two days at 37uC and the allantoic fluid containing virus was
harvested, filtered and stored in 280uC until use. The use of this
virus has been described elsewhere [48].
NDV infection assay
0.5 million A549 cells were seeded in 12 well plates twelve hours
prior to stimulation. Cells were stimulated in the presence of poly
I:C (100 mg/ml) for 24 hours. Cells were washed with PBS and
20 ml (MOI 1) of NDV-GFP virus was added in 180 ml of PBS
(with Ca and Mg) and left at 37uC for 1 hour. Cells were then
washed with PBS and incubated in fresh F12K media followed by
fixation and imaging. GFP signal started to appear after 12 hours
but peaked at 24 hours post-infection. DAPI was added to stain
nuclei.
Immunofluorescence staining and Confocal Microscopy
Transfected Huh7.5.1 cells were fixed in 2% paraformaldehyde
(15 min, RT), permeablized with 0.1% (v/v) Triton X-100 in PBS
three times (PBST; 10 min, RT), and blocked in 0.3% (w/v)
bovine serum albumin (BSA) in PBS (45 minutes, RT), and
subsequently incubated in PBS (1 h, RT) with anti-Flag M2
antibody (1:500). Samples were washed in PBS and subsequently
incubated with Alexa 568 secondary antibodies diluted in PBS
(1:500). Nucleus was stained with Draq5 (Biostatus, United
Kingdom). Samples were mounted on a slide using a homemade
Gelvatol mounting medium. Images were captured on a Carl Zeiss
Meta LSM 510 confocal microscope (606Plan-Neo/1.3 NA Oil)
and edited by Photoshop (Adobe).
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